Neisseria meningitidis polysaccharide conjugated to tetanus toxoid
As of the edition of 20 October 2026, Neisseria meningitidis polysaccharide conjugated to tetanus toxoid is a vaccine component: marketed, first approved in 2020 (US); US protection ends in 2032.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2020
- Kind
- Vaccine component
- Brand name
- Menquadfi
- First approved
- 23 April 2020 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Sanofi
- Registered trials
- 40, 1 stopped early
- Disease areas
- Infections; Nervous system; Lungs and airways
US protection
US protection ends in 2032.
The reference-product exclusivity ends in 2032. The application that gives this date is held by Sanofi.
This is the US only, and it is not the date generics or biosimilars can enter.
The exact date and the listings behind it
In the product1 listing counts towards this date. The exact date and each listing are in the product.
See the exact date and the 1 listing behind itRequest access. Nothing is shown until you do.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 1 | 0 |
| Phase 2 | 7 | 6 | 0 | 1 |
| Phase 3 | 30 | 29 | 1 | 0 |
| Phase 4 | 2 | 2 | 0 | 0 |
| All trials | 40 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| GSK | Lead sponsor of trials | 2007 to now |